Dubai Ruler Funds Zolgensma Gene Therapy for Children with Spinal Muscular Atrophy
核心洞察
Sheikh Mohammed bin Rashid Al Maktoum has ordered full funding for an 11-year-old Iraqi boy with spinal muscular atrophy (搜索) who faces a roughly two-month treatment window.
The intervention follows his coverage of the full $2.4 million (Dh8.8 million) Zolgensma treatment for 16-month-old Jordanian toddler Katia Abu Al Saud.
Katia traveled from Amman to Dubai to begin treatment at Al Jalila Children's Hospital (搜索), where she is expected to receive the one-time gene therapy Zolgensma.
His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, has stepped in to fund treatment for an 11-year-old Iraqi boy with spinal muscular atrophy (搜索) (SMA) who has only about two months remaining to receive the care required for his condition. The announcement, made on Sunday, gives the child and his family renewed hope after a prolonged effort to secure help.
Abdulrahman Muhannad Al Ajili, who is 11 years and 10 months old, is at a critical stage in his treatment journey, with the window for receiving the appropriate therapy narrowing rapidly. Sheikh Mohammed has ordered covering the treatment, though details of the therapy, including its cost and where it will be administered, have not yet been publicly disclosed.
A Second Intervention Within Days
The intervention comes little more than a week after Sheikh Mohammed stepped in to cover the full treatment for Katia Abu Al Saud, a 16-month-old Jordanian girl with spinal muscular atrophy (搜索) whose family had appealed publicly for help after being told the therapy she needed was unavailable in Jordan.
Katia travelled from Amman to Dubai with her mother, Nour Roudnahal, on Saturday to begin treatment at Al Jalila Children's Hospital (搜索). Sheikh Mohammed is covering the full $2.4 million, or about Dh8.8 million, cost of her treatment, which is expected to involve Zolgensma, a one-time gene therapy used for children with SMA.
The Zolgensma Gene Therapy
Zolgensma is a one-time gene therapy used to treat young children with SMA, a rare genetic condition that causes progressive muscle weakness. Doctors in Jordan had told Katia's family that the therapy she needed was not available locally, prompting her mother to turn to social media in search of assistance.
The Dubai Media Office announced on Aug. 20 that Sheikh Mohammed would cover the cost of Katia's treatment and that it would be provided at Al Jalila Children's Hospital (搜索). The announcement brought an abrupt change to a family that had spent months worrying about whether it could secure treatment in time.
Restoring Hope for Families
Katia's father, Omar Abu Al Saud, said that Sheikh Mohammed's intervention is restoring hope to the family after a long period of anxiety, saying it had given his daughter a new chance to receive the treatment she needs.
The two cases underscore both the transformative potential of gene therapy for SMA and the substantial financial barriers families face in accessing it. With treatment costs reaching $2.4 million and availability limited in the region, philanthropic intervention has become a critical pathway to timely care for children facing narrow treatment windows.